Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Feb 25,2021
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
On February 22, 2021, Nanjing TransThera Biosciences Co., Ltd. ("TransThera”) and the life science company of South Korea's LG Chem ("LG Chem”) jointly announced the
More
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
Feb 10,2021
Happy Chinese New Year
Thank you for your business, support and partnership in 2020!  Medicilon appreciates working with you and hope that the coming year will bring you happiness
More
Happy Chinese New Year
Feb 08,2021
3D011-08 from 3D Medicines was approved of conducting clinical trials
Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines
More
3D011-08 from 3D Medicines was approved of conducting clinical trials
Feb 08,2021
Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610
Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610
More
Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610
Jan 13,2021
Medicilon was Awarded the Excellent Academician and Expert Workstation of Shanghai and Pudong New Area
Recently, Shanghai Medicilon was awarded the title of "Excellent Expert Workstation” by the Shanghai Academician and Expert Workstation Guidance Office and the title of "2020
More
Medicilon was Awarded the Excellent Academician and Expert Workstation of Shanghai and Pudong New Area
Jan 04,2021
Medicilon's Top 10 Greatest Achievements in 2020
Medicilon embodies its motto of being "Innovation-driven, quality-focused" and keeps on maintaining and improving its technology and quality of services.
More
Medicilon's Top 10 Greatest Achievements in 2020
Jan 01,2021
Medicilon's pharmacology models for inflammatory-immune diseases
Inflammatory immune diseases have gained much attention as the incidence has grown bigger each year. The diseases can affect many parts of human bodies and
More
Medicilon's pharmacology models for inflammatory-immune diseases
Dec 25,2020
Medicilon is Listed as the 2020 TOP10 Innovation CRO in China
Dec.20, 2020, Hebei—The 13th China Pharmaceutical Strategy Conference 2020 was held successfully. The conference presented the list of "the 2020 TOP10 Innovation CRO in China”.
More
Medicilon is Listed as the 2020 TOP10 Innovation CRO in China
Dec 25,2020
Medicilon's CDMO Service Platform
Medicilon has constructed the GMP Drug Products Pilot Plant to meet the rising needs for innovative medicine R&D, production, packaging, inspections and stability tests.
More
Medicilon's CDMO Service Platform
Dec 22,2020
Warmest Holiday Season Greeting From Medicilon 2021
Warmest Holiday Season Greeting From Medicilon. Medicilon wishes you peace,joy and prosperity throughout the coming year.
More
Warmest Holiday Season Greeting From Medicilon 2021
Dec 04,2020
CGeneTech and Medicilon Held the Conference Titled "PROTAC Project Contract Signing & Kick-off Meeting”
Shanghai, China, Dec. 2nd, 2020 — CGeneTech (Suzhou, China) Co., Ltd and Medicilon Inc. successfully held the conference titled "PROTAC project contract signing & kick-off
More
CGeneTech and Medicilon Held the Conference Titled "PROTAC Project Contract Signing & Kick-off Meeting”
Dec 01,2020
Medicilon's Immuno-oncology Models Evaluation Platform
In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as the driving force, Medicilon has vigorously developed a tumor
More
Medicilon's Immuno-oncology Models Evaluation Platform
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->